ABSTRACT
When the SEGH international board released a short editorial paper back in 2019, we described an aim to increase the membership offering, whilst improving the diversity of input regionally, by scientific discipline and to ensure greater and more regular contact across the regions from 2020 onwards. Wider aspirations described in 2019 (Watts et al. 2019) are discussed within this short communication at the end of 2021 to evaluate progress made. In particular, how the SEGH community adapted to the unprecedented circumstances that have challenged each and every one of us throughout the COVID-19 pandemic since early 2020 and are likely to influence our activities for the foreseeable future.
ABSTRACT
A 17-year-old-male presented to an acute medical take with severe mouth pain, and poor oral intake. This occurred 6 days after a positive SARS CoV-2 test, with which he had only mild symptoms. He was unvaccinated against SARS CoV-2. Clinically, he had a severe ulcerated mucositis present on his lips, buccal mucosa and lateral edge of the tongue. He had not been commenced on any new medications prior. There was no other skin involvement. Viral swabs for herpes simplex virus and varicella zoster virus were negative. His presentation was in keeping with a reactive infectious mucocutaneous eruption (RIME) secondary to COVID-19 infection. This typically presents with severe painful mucositis with mild nonspecific skin manifestations. This entity was previously classically described in association with Mycoplasma infection. Since the emergence of COVID-19, several cutaneous manifestations have been observed. There is only one other published case of RIME associated with COVID-19 infection. This was in a similarly aged male presenting with severe mucositis and lack of significant cutaneous involvement. The patient was treated with a 5-day course of 40 mg oral prednisolone, which led to complete resolution with no scarring or subsequent recurrence. A literature review revealed only one other case of RIME associated with COVID-19, which was successfully treated with oral steroid therapy. The case exemplifies new, emerging presentations related to COVID-19 infection that may present to dermatology services.